209 related articles for article (PubMed ID: 25553114)
1. Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.
Li QK; Chen L; Ao MH; Chiu JH; Zhang Z; Zhang H; Chan DW
Theranostics; 2015; 5(3):267-76. PubMed ID: 25553114
[TBL] [Abstract][Full Text] [Related]
2. Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA.
Wang C; Höti N; Lih TM; Sokoll LJ; Zhang R; Zhang Z; Zhang H; Chan DW
Clin Proteomics; 2019; 16():13. PubMed ID: 30996714
[TBL] [Abstract][Full Text] [Related]
3. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
4. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA.
Haga Y; Uemura M; Baba S; Inamura K; Takeuchi K; Nonomura N; Ueda K
Anal Chem; 2019 Feb; 91(3):2247-2254. PubMed ID: 30669833
[TBL] [Abstract][Full Text] [Related]
5. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
Song J; Ma S; Sokoll LJ; Eguez RV; Höti N; Zhang H; Mohr P; Dua R; Patil D; May KD; Williams S; Arnold R; Sanda MG; Chan DW; Zhang Z
Theranostics; 2021; 11(13):6214-6224. PubMed ID: 33995654
[No Abstract] [Full Text] [Related]
6. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.
Llop E; Ferrer-Batallé M; Barrabés S; Guerrero PE; Ramírez M; Saldova R; Rudd PM; Aleixandre RN; Comet J; de Llorens R; Peracaula R
Theranostics; 2016; 6(8):1190-204. PubMed ID: 27279911
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the main PSA glycoforms in aggressive prostate cancer.
Gratacós-Mulleras A; Duran A; Asadi Shehni A; Ferrer-Batallé M; Ramírez M; Comet J; de Llorens R; Saldova R; Llop E; Peracaula R
Sci Rep; 2020 Nov; 10(1):18974. PubMed ID: 33149259
[TBL] [Abstract][Full Text] [Related]
8. LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.
Inoue T; Kaneko T; Muramatsu S; Kimura H; Yoshino T; Goto T; Sawada A; Akamatsu S; Kobayashi T; Yamasaki T; Kaya T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e28-e36. PubMed ID: 31711843
[TBL] [Abstract][Full Text] [Related]
9. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
Yoneyama T; Ohyama C; Hatakeyama S; Narita S; Habuchi T; Koie T; Mori K; Hidari KI; Yamaguchi M; Suzuki T; Tobisawa Y
Biochem Biophys Res Commun; 2014 Jun; 448(4):390-6. PubMed ID: 24814705
[TBL] [Abstract][Full Text] [Related]
10. Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer.
Fujita K; Hayashi T; Matsuzaki K; Nakata W; Masuda M; Kawashima A; Ujike T; Nagahara A; Tsuchiya M; Kobayashi Y; Nojima S; Uemura M; Morii E; Miyoshi E; Nonomura N
Oncotarget; 2016 Aug; 7(35):56643-56649. PubMed ID: 27494861
[TBL] [Abstract][Full Text] [Related]
11. Serum core-type fucosylated prostate-specific antigen index for the detection of high-risk prostate cancer.
Fujita K; Hatano K; Tomiyama E; Hayashi Y; Matsushita M; Tsuchiya M; Yoshikawa T; Date M; Miyoshi E; Nonomura N
Int J Cancer; 2021 Jun; 148(12):3111-3118. PubMed ID: 33594666
[TBL] [Abstract][Full Text] [Related]
12. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
[TBL] [Abstract][Full Text] [Related]
13. Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection.
Kekki H; Peltola M; van Vliet S; Bangma C; van Kooyk Y; Pettersson K
Clin Biochem; 2017 Jan; 50(1-2):54-61. PubMed ID: 27818346
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
17. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
[TBL] [Abstract][Full Text] [Related]
18. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
[TBL] [Abstract][Full Text] [Related]
19. Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases.
de Charry F; Colomban O; You B; Ruffion A; Paparel P; Wilbaux M; Tod M; Freyer G; Perrin P
Clin Genitourin Cancer; 2016 Jun; 14(3):210-217.e1. PubMed ID: 26804605
[TBL] [Abstract][Full Text] [Related]
20. An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example.
Lang R; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Vogeser M
Clin Chim Acta; 2018 May; 480():1-8. PubMed ID: 29408166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
